Evidence Explorer · MS-N249 · Mind–body and sleep · insomnia during chemotherapy · Appraised November 6, 2026
For women receiving chemotherapy for breast cancer, a six-week cognitive behavioral therapy for insomnia (CBT-I) program improved insomnia severity, while bright-light therapy did not; neither intervention improved fatigue in the primary factorial analysis.
Evidence at a glance
- Benefit signal: A modest insomnia benefit from CBT-I; no convincing benefit from bright light and no fatigue benefit.
- Certainty: Moderate for the short-term insomnia finding, lower for subgroup and combined-treatment interpretations.
- Risk context: CBT-I is usually low risk but sleep restriction can temporarily increase sleepiness. Light treatment warrants extra care with bipolar disorder, severe eye disease or photosensitizing medicines.
- Cancer-control relevance: This was symptom-support research. It did not test tumor response, recurrence or survival.
What was studied
The SleepCARE randomized trial enrolled 219 women with early or metastatic breast cancer receiving chemotherapy. It used a 2×2 factorial design: CBT-I versus sleep-hygiene education and bright-light therapy versus placebo light for six weeks; 208 participants contributed to the primary analysis.
The primary outcomes were insomnia severity and fatigue. The research regimens were behavioral treatments, not anticancer therapy.
What the study found
CBT-I reduced Insomnia Severity Index scores by an adjusted 2.19 points more than the comparison condition (95% CI −3.33 to −1.05; p=.002). The fatigue difference was −0.90 points (95% CI −3.08 to 1.28), compatible with no material effect.
Bright light did not significantly improve insomnia (difference −0.88; 95% CI −2.02 to 0.26) or fatigue (−0.71; 95% CI −2.89 to 1.47). Exploratory subgroup findings should not override these primary results.
What this does not establish
The average insomnia difference was statistically persuasive but smaller than commonly used individual-response thresholds. Treatment lasted six weeks, and the results do not establish long-term durability.
The study does not support bright light as a cancer treatment or infer cancer control from better sleep.
Safety and practical context
CBT-I is best adapted when chemotherapy, pain, hot flashes, steroid timing or irregular sleep are driving insomnia. Marked daytime sleepiness can affect driving and fall risk while sleep schedules are being compressed.
Light boxes vary in intensity and spectral output. People with bipolar-spectrum illness, retinal disease or photosensitizing drugs should discuss light treatment with the relevant clinician.
Questions for the care team
- Is this persistent insomnia suitable for CBT-I, and is a trained clinician or validated digital program available?
- Do chemotherapy timing, corticosteroids, pain or hot flashes need separate treatment?
- Would light treatment create an eye, mood or medication-sensitivity concern?
Sources and identifiers
Funding and conflicts: Funding and complete conflict disclosures were checked in the primary report; they should be interpreted alongside the authors’ declarations rather than assumed absent.
Source access and dates: Primary journal report and PubMed record were appraised. Sources checked November 6, 2026. Last literature search November 6, 2026.
Educational evidence summary, not individualized medical advice. Psychological and sleep interventions should complement—not replace—oncology, palliative, mental-health or sleep-medicine care.
